Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

B. Brodská, P. Otevřelová, C. Šálek, O. Fuchs, Z. Gašová, K. Kuželová,

. 2019 ; 20 (11) : . [pub] 20190610

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044765

Grantová podpora
grant No 16-30268A and project for conceptual development of the research organization No 00023736. Ministerstvo Zdravotnictví Ceské Republiky
NV16-30268A MZ0 CEP - Centrální evidence projektů

Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas. However, several studies indicated that PD-L1 is also overexpressed in myeloid malignancies. Successful treatment of the acute myeloid leukemia (AML) is likely associated with elimination of the residual disease by the immune system, and possible involvement of PD-L1 in this process remains to be elucidated. We analyzed PD-L1 expression on AML primary cells by flow cytometry and, in parallel, transcript levels were determined for the transcription variants v1 and v2. The ratio of v1/v2 cDNA correlated with the surface protein amount, and high v1/v2 levels were associated with worse overall survival (p = 0.0045). The prognostic impact of PD-L1 was limited to AML with mutated nucleophosmin and concomitant internal tandem duplications in the FLT3 gene (p less than 0.0001 for this particular AML subgroup).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044765
003      
CZ-PrNML
005      
20200113081304.0
007      
ta
008      
200109s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms20112823 $2 doi
035    __
$a (PubMed)31185600
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Brodská, Barbora $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. brodska@uhkt.cz.
245    10
$a High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations / $c B. Brodská, P. Otevřelová, C. Šálek, O. Fuchs, Z. Gašová, K. Kuželová,
520    9_
$a Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas. However, several studies indicated that PD-L1 is also overexpressed in myeloid malignancies. Successful treatment of the acute myeloid leukemia (AML) is likely associated with elimination of the residual disease by the immune system, and possible involvement of PD-L1 in this process remains to be elucidated. We analyzed PD-L1 expression on AML primary cells by flow cytometry and, in parallel, transcript levels were determined for the transcription variants v1 and v2. The ratio of v1/v2 cDNA correlated with the surface protein amount, and high v1/v2 levels were associated with worse overall survival (p = 0.0045). The prognostic impact of PD-L1 was limited to AML with mutated nucleophosmin and concomitant internal tandem duplications in the FLT3 gene (p less than 0.0001 for this particular AML subgroup).
650    _2
$a antigeny CD274 $x krev $x genetika $x metabolismus $7 D060890
650    _2
$a nádorové biomarkery $x krev $x genetika $x metabolismus $7 D014408
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x krev $x genetika $7 D015470
650    _2
$a mutace $7 D009154
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941
655    _2
$a časopisecké články $7 D016428
700    1_
$a Otevřelová, Petra $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Petra.Otevrelova@uhkt.cz.
700    1_
$a Šálek, Cyril $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Cyril.Salek@uhkt.cz.
700    1_
$a Fuchs, Ota $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Ota.Fuchs@uhkt.cz.
700    1_
$a Gašová, Zdenka $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. Zdenka.Gasova@uhkt.cz.
700    1_
$a Kuželová, Kateřina $u Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic. kuzelova@uhkt.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 20, č. 11 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31185600 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081636 $b ABA008
999    __
$a ok $b bmc $g 1483034 $s 1083438
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 20 $c 11 $e 20190610 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a grant No 16-30268A and project for conceptual development of the research organization No 00023736. $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NV16-30268A $p MZ0
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace